Evaluating Anticancer Activity of a Cobalt(III) Complex with a Thiosemicarbazone Ligand Against Triple Negative Breast Cancer Cells
Description/Abstract/Artist Statement
Cancer is one of the major causes of death in the world. Breast cancer is an uncontrolled growth of epithelial cells of the breast. Triple negative breast cancer (TNBC), a subtype of breast cancer, lacks estrogen, progesterone, and HER2 receptors. Chemotherapeutic options for TNBC which involves cisplatin have severe side effects, e.g., cytotoxicity of normal breast tissue, drug resistance, and breast cancer recurrence. The objective of this study was to determine less toxic treatment options for TNBC by using a cobalt(III) complex, which like most conventional anticancer drugs was designed to disrupt DNA synthesis as a chemotherapeutic agent. Previously, [Co(phen)2(H2O)2](NO3)3 1 (where phen = 1,10-phenanthroline) was reacted with 9-anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) to produce [Co(phen)2(MeATSC)](NO3)3·1.5H2O·C2H5OH 2. The hypothesis is as follows: complex 2 will have a higher anticancer effect on TNBC cell line MDA-MB-231-VIM-RFP than cisplatin. In vitro cytotoxicity studies involving complex 2 with MDA-MB-231-VIM-RFP were carried out by using the Cell Counting Kit-8 (CCK-8) assay. The anti-proliferative activity of complex 2 was evaluated after incubating the drug with MDA-MB-231-VIM-RFP cells in increasing concentrations (0, 6.125, 12.5, 25, 50, and 100 μM) for 24 hours, then cell viability was measured by CCK-8 assay. Dose curves and doses required to inhibit 50% of cell growth (IC50 values) were obtained by using Origin Pro software, which revealed that MDA-MB-231-VIM-RFP cell viability was negatively impacted by complex 2 with an IC50 value of ~26 μM.
Faculty Advisor/Mentor
Alvin Holder
College Affiliation
College of Sciences
Presentation Type
Oral Presentation
Disciplines
Biochemistry, Biophysics, and Structural Biology | Cell and Developmental Biology | Chemistry
Session Title
Monarchs Maximizing Access to Research Careers #2
Location
Zoom Room I
Start Date
3-20-2021 10:00 AM
End Date
3-20-2021 10:55 AM
Evaluating Anticancer Activity of a Cobalt(III) Complex with a Thiosemicarbazone Ligand Against Triple Negative Breast Cancer Cells
Zoom Room I
Cancer is one of the major causes of death in the world. Breast cancer is an uncontrolled growth of epithelial cells of the breast. Triple negative breast cancer (TNBC), a subtype of breast cancer, lacks estrogen, progesterone, and HER2 receptors. Chemotherapeutic options for TNBC which involves cisplatin have severe side effects, e.g., cytotoxicity of normal breast tissue, drug resistance, and breast cancer recurrence. The objective of this study was to determine less toxic treatment options for TNBC by using a cobalt(III) complex, which like most conventional anticancer drugs was designed to disrupt DNA synthesis as a chemotherapeutic agent. Previously, [Co(phen)2(H2O)2](NO3)3 1 (where phen = 1,10-phenanthroline) was reacted with 9-anthraldehyde-N(4)-methylthiosemicarbazone (MeATSC) to produce [Co(phen)2(MeATSC)](NO3)3·1.5H2O·C2H5OH 2. The hypothesis is as follows: complex 2 will have a higher anticancer effect on TNBC cell line MDA-MB-231-VIM-RFP than cisplatin. In vitro cytotoxicity studies involving complex 2 with MDA-MB-231-VIM-RFP were carried out by using the Cell Counting Kit-8 (CCK-8) assay. The anti-proliferative activity of complex 2 was evaluated after incubating the drug with MDA-MB-231-VIM-RFP cells in increasing concentrations (0, 6.125, 12.5, 25, 50, and 100 μM) for 24 hours, then cell viability was measured by CCK-8 assay. Dose curves and doses required to inhibit 50% of cell growth (IC50 values) were obtained by using Origin Pro software, which revealed that MDA-MB-231-VIM-RFP cell viability was negatively impacted by complex 2 with an IC50 value of ~26 μM.